We are developing in-situ CAR-macrophage therapies for solid tumours — reprogramming the immune cells already inside the tumour to recognise and clear cancer.
Get in touchCell therapy has transformed the treatment of blood cancers but has struggled against solid tumours, where engineered cells infiltrate poorly and per-patient manufacturing limits reach. Vorcella takes a different route: rather than building cells outside the body, we work with the immune cells already inside the tumour.
Macrophages naturally infiltrate solid tumours — the compartment that has been hardest for cell therapy to reach.
We reprogram tumour macrophages in situ, avoiding the cost and complexity of ex-vivo cell manufacturing.
An approach designed around an off-the-shelf product — the logistics profile of a biologic, not a bespoke therapy.
Solid tumours account for the overwhelming majority of cancer deaths, yet remain largely out of reach for today's cell therapies. Our work is focused squarely on this gap.
We are advancing a platform designed to be retargeted across multiple solid-tumour indications, beginning with a defined lead programme and expanding from a single construct and delivery system.
For partnering, investment, or scientific enquiries, please reach out.